Survivors’ perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group-Reference-Cited by-同舟云学术

Survivors’ perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group

Published:2018-12-03 Issue:6 Volume:60 Page:1389-1398
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kreissl Stefanie¹,Goergen Helen¹,Müller Horst¹,Meissner Julia²,Mehnert Anja³,Bürkle Carolin¹,Fuchs Michael¹,Engert Andreas¹,Behringer Karolin¹,Borchmann Peter¹

Affiliation:

1. German Hodgkin Study Group (GHSG), Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany;

2. University of Heidelberg, Heidelberg, Germany;

3. Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1540781

Reference28 articles.

1. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

2. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

3. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

4. Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease

5. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial;The Lancet;2024-07

2. Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability;Oncotarget;2023-12-12

3. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma;Leukemia;2023-10-16

4. Comparing revised latent state–trait models including autoregressive effects.;Psychological Methods;2022-08-04

5. Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy;Leukemia & Lymphoma;2022-07-29